Early-stage study of OncoMed's GITRL-Fc underway; shares up 1%

|About: OncoMed Pharmaceutical... (OMED)|By:, SA News Editor

The first patient has been dosed in a Phase 1a study assessing the safety and tolerability of OncoMed Pharmaceuticals' (OMED +0.9%) GITRL-Fc (OMP-336B11) in patients with advanced or metastatic solid tumors.

GITRL-Fc is a fusion protein, a costimulatory molecule designed to modulate the tumor microenvironment by inhibiting T-regulatory function and activating T-effector cells.